BioSpace News Archive

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the issuance of U.S. Patent No. 11,459,363.

Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the appointment of Paul A. Smith, Ph.D., as senior vice president of biology.

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Pfizer Inc. (NYSE: PFE) for the CDK4/6 inhibitor palbociclib (IBRANCE®).

T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced it has dosed the first patient in the IMAG1NE Phase 1/2 clinical trial.

OrthoPediatrics Corp. today announced the appointment of Jimmy D. McDonald to its board of directors, effective October 18, 2022.

Belite Bio, Inc will host a key opinion leader (KOL) event with a focus on LBS-008 (aka Tinlarebant), the Company’s lead asset for the treatment of Stargardt Disease (STGD1) and Dry Age-Related Macular Degeneration (Dry AMD) on Thursday, October 27, 2022 at 11 a.m. Eastern Time.

Sunshine Biopharma Inc. today announced that it has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately.

Healthcare technology company Kalderos, creator of the healthcare industry’s first Drug Discount Management platform, today announced Lisa Bomrad as its first Chief People Officer.

Creative Medical Technology Holdings, Inc. announced today that through predominantly internal and collaborative development, it has produced an allogenic Cell Line called AlloStem.

U.S. Patent No. 11,471,431 relates to the use of LP-300 to increase the survival time of patients with cancers overexpressing thioredoxin or glutaredoxin.